Rx Products (July 2020)
Prescription products are featured.
SELPERCATINIB (RETEVMO)MANUFACTURED BY: Loxo Oncology, Inc
The FDA recently approved selpercatinib, a kinase inhibitor indicated for non—small cell lung cancer (NSCLC), medullary thyroid cancer, and other types of thyroid cancers in patients whose tumors have rearranged during transfection mutation. Results of the drug’s efficacy in NSCLC demonstrated that 585 patients who responded to the treatment had a response lasting at least 6 months. The most common adverse effects included increased aspartate aminotransferase and alanine aminotransferase enzymes in the liver, increased blood sugar, decreased albumin in the blood, and a lower white blood cell count.
FOR MORE INFORMATION: retevmo.com
DAPAGLIFLOZIN (FARXIGA)MANUFACTURED BY: AstraZeneca
The FDA has approved dapagliflozin to decrease the risk of cardiovascular death and hospitalization from heart failure in adults with reduced ejection fraction, with and without type 2 diabetes (T2D). It is the first sodium glucose cotransporter 2 inhibitor approved for this condition, after being granted priority review and fast track designations. The drug was previously approved in 2019 to reduce the risk of hospitalization for heart failure in adults with T2D and established cardiovascular disease.
FOR MORE INFORMATION: farxiga.com
CAPMATINIB (TABRECTA)MANUFACTURED BY: Novartis Pharmaceuticals Corporation
Capmatinib is the first FDA-approved therapy to treat specific mutations of non—small cell lung cancer that have spread to other parts of the body. As a kinase inhibitor, it blocks a key enzyme that helps stop the tumor cells from growing. In the clinical trial, participants receiving the drug had an overall response rate of 68%, with 4% having a complete response. Common adverse effects (AEs) included decreased appetite, dyspnea, fatigue, nausea, peripheral edema, and vomiting. Serious AEs can include interstitial lung disease or pneumonitis.
FOR MORE INFORMATION: us.tabrecta.com
LEUPROLIDE ACETATE (FENSOLVI)MANUFACTURED BY: Tolmar Pharmaceuticals
The FDA has approved leuprolide acetate injectable suspension for the treatment of pediatric patients aged 2 years and older with central precocious puberty, a rare disease defined as the onset of puberty before age 8 in girls and before age 9 in boys. The drug uses a proprietary polymeric gel technology that forms an in situ solid after injection and releases the drug in a controlled and sustained manner. Studies found that the drug suppressed sex hormones to prepubertal levels and reversed or stopped the progression of clinical signs of puberty. Treatment-emergent adverse events were mostly mild or moderate and included injection site pain (31%), nasopharyngitis (22%), and fever (17%).
FOR MORE INFORMATION: fensolvi.com